Considerations for the Use of Checkpoint Inhibitors in Gastroesophageal Cancers

Get an expert&rsquo s take on the evolving role of immune checkpoint inhibitors in managing advanced gastric and esophageal cancers with this program which features a series of ClinicalThought&trade commentaries on emerging clinical data managing immune-related adverse events and key biomarkers of response.

Share

Program Content

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb